Summary: Levodopa remains the leading therapy for Parkinson’s disease, and catechol-O-methyltransferase inhibitors (COMT-Is) are routinely prescribed to enhance levodopa’s effect. New research from Yale reveals an unexpected drug–microbiome interaction: COMT-Is can act like antibiotics in the gut, killing beneficial microbes and enabling a levodopa-degrading bacterium, Enterococcus faecalis, to expand and metabolize the medication before it reaches the brain.
The study demonstrates that a commonly used adjunct therapy can unintentionally undermine levodopa by reshaping the intestinal microbiome. This finding highlights the gut as an active site for drug–drug interactions and offers an explanation for why some patients respond differently to the same Parkinson’s treatment.
Key Facts
- The microbiome as mediator: Rather than occurring only through liver enzymes, some drug interactions are driven by changes in gut microbial communities that influence how drugs are metabolized.
- COMT-Is show antibacterial activity: The researchers found that COMT inhibitors can kill microbiota species susceptible to their off-target effects, creating ecological space that favors hardier bacteria.
- Enterococcus faecalis metabolizes levodopa: When E. faecalis proliferates, enzymes it carries chemically modify levodopa in the gut, preventing the drug from crossing the blood–brain barrier and lowering central dopamine production.
- Explains patient variability: Differences in individual microbiome composition may account for why the same levodopa regimen works well for some patients but not for others.
- Wider implications: The lead author suggests similar microbiome-mediated interactions could occur in other conditions treated with multiple drugs, indicating the need to evaluate co-prescribed medications through a microbial lens.
Source: Yale
Levodopa remains the gold-standard therapy for Parkinson’s disease, supplying a precursor that the brain converts to dopamine. As symptoms advance, clinicians frequently add drugs such as COMT inhibitors to boost levodopa’s availability. COMT-Is are intended to block enzymes that would otherwise chemically modify and inactivate levodopa before it reaches the central nervous system.
Yale School of Medicine researchers, publishing in Nature Microbiology, show that COMT-Is can change gut community structure, promoting bacteria that metabolize levodopa. In vitro, ex vivo and in vivo experiments revealed that COMT-Is possess antibacterial properties that eliminate susceptible species, allowing levodopa-degrading bacteria to expand.
Lead author Andrew Verdegaal, PhD, explains that the observed interaction is counterproductive: a drug designed to preserve levodopa’s activity indirectly reduces its effectiveness by altering the microbiome. This mechanism operates independently of the liver and underlines the gut’s role in drug response.
How bacterial changes reduce levodopa effectiveness
Parkinson’s disease symptoms arise from reduced dopamine in the brain. Oral levodopa is absorbed from the gut and must reach the brain intact to be converted into dopamine. Enzymes in the body or in gut microbes can transform levodopa into compounds that cannot cross the blood–brain barrier, reducing therapeutic benefit.
COMT inhibitors are intended to block these modifying enzymes in the host. However, the Yale study shows COMT-Is can also act on gut microbes: by killing certain bacteria, they create an environment in which Enterococcus faecalis—which carries enzymes that metabolize levodopa—can thrive. As E. faecalis increases, more levodopa is degraded in the intestine and less is available to the brain, which may explain reduced symptom control in some patients.
The findings reiterate earlier observations linking high E. faecalis abundance with diminished levodopa benefit and suggest clinicians should consider the microbiome when evaluating treatment failure.
Key Questions Answered:
A: Many medications produce off-target effects. The chemical properties of some COMT inhibitors make them toxic to particular gut bacteria, reducing those populations and unintentionally favoring more resilient microbes such as E. faecalis.
A: Simply adding probiotics is unlikely to be a reliable solution while the COMT-Is continue to exert antibacterial pressure. The study points toward future strategies—targeted therapies, microbiome-friendly drug formulations, or dietary approaches—that could prevent E. faecalis overgrowth without compromising levodopa treatment.
A: No. COMT inhibitors remain valuable for many patients. This research provides clinicians with an added perspective: if a patient’s symptoms worsen despite appropriate dosing, the cause may be microbiome-mediated drug degradation rather than failure of levodopa itself. Clinical decisions should continue to be individualized and guided by a physician.
Editorial Notes:
- This article was edited by an editor at Neuroscience News.
- The original journal paper was reviewed in full by the editorial team.
- Additional context and clarification were provided by staff writers to aid understanding.
About this neuropharmacology and Parkinson’s disease research news
Author: Colleen Moriarty
Source: Yale School of Medicine
Contact: Colleen Moriarty – Yale
Image: Image credit: Neuroscience News
Original Research: Open access.
Title: A drug–microbiome–drug interaction impacts co-prescribed medications for Parkinson’s disease
Authors: Andrew A. Verdegaal, Joonseok Oh, Bahar Javdan, Ruojun Wang, Qihao Wu, Timothy R. W. Wang, Jaime A. González-Hernández, Mohamed S. Donia, Jason M. Crawford & Andrew L. Goodman
Journal: Nature Microbiology
DOI: 10.1038/s41564-026-02299-2
Abstract (summary)
Simultaneous prescription of multiple drugs is common. Although the gut microbiome is known to affect individual drug responses, its role in mediating interactions between co-prescribed medications has been underexplored. This study characterizes the antibiotic-like activity of COMT inhibitors in laboratory, community and animal models and shows how these effects reshape microbiome composition and levodopa metabolism in an individual-specific manner. The researchers identify iron availability as a factor modifying COMT-I activity and demonstrate that co-administration of COMT-Is and levodopa can alter levodopa processing by human fecal communities. These results underscore the gut microbiome’s potential to drive drug–drug interactions and suggest microbial markers that might predict individual responses to combined therapies.